<DOC>
	<DOC>NCT01433666</DOC>
	<brief_summary>The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans.</brief_summary>
	<brief_title>Roflumilast and Cognition</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<criteria>18 to 35 years of age Healthy (i.e. absence of all exclusion criteria), normal static binocular acuity (corrected or uncorrected), Body mass index between 18.5 and 30 Willingness to sign an informed consent. Positive evaluation on the memory screening History of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric illness Firstdegree relative with psychiatric disorder (in particular major depressive disorder and suicidality) Excessive drinking (&gt;20 glasses of alcohol containing beverages per week) Pregnancy or lactation Use of chronic medication other than oral contraceptives Use of recreational drugs in the 2 weeks preceding participation Smoking Orthostatic hypotension Lactose intolerance Sensory or motor deficits which could reasonably be expected to affect test performance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>